Roni Shouval
@RShouval
Followers
1K
Following
1K
Media
87
Statuses
853
Precision Cellular Therapy | Attending - BMT and Cellular Therapy Service @sloan_kettering
Manhattan, NY
Joined December 2018
🚨 Just out @NatureMedicine! Introducing InflaMix—a point-of-care tool that identifies an #inflammatory 🔥 signature predictive of #CART failure in #lymphoma Led by Sandeep Raj (@SSRaj017) 👏@MSKCancerCenter
https://t.co/k0tQMZBSxS 🧵Let’s break it down
nature.com
Nature Medicine - A preinfusion circulatory inflammation biomarker-based signature predicts the likelihood of treatment failure in patients with non-Hodgkin lymphoma who were treated with CAR-T...
4
42
152
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma | Journal of Clinical Oncology
ascopubs.org
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Here, we report updated...
0
0
0
Microenvironmental regulation of solid tumour resistance to CAR T cell therapy
nature.com
Nature Reviews Immunology - The tumour microenvironment (TME) poses a significant obstacle to the success of chimeric antigen receptor (CAR) T cell immunotherapy in solid tumours. Here, the authors...
2
58
190
#OnlineFirst Timing Genomic Antigen Loss in #MultipleMyeloma Treated with T Cell–Redirecting Immunotherapies https://t.co/RBGZzjG1Gu
0
4
2
Thank you to @CGAIGC for selecting our abstract for an oral presentation and to @JCOPO_ASCO for the simultaneous publication and podcast!
@asaf_maoz presented data on causes of death among individuals with #LynchSyndrome in the immunotherapy era at #CGAIGC25 w/simultaneous publication in @JCOPO_ASCO
https://t.co/17QNJmI6nV 📢MSS tumors were a frequent cause of death 📢Enriched for pancreatic cancer & glioblastoma
0
4
22
CONGRESS | #IACH | PRESENTATION Roni Shouval @RShouval @MSKCancerCenter provides an overview of CAR T-cell mechanisms of resistance and potential therapeutic strategies to overcome resistance. Follow our live feed for more updates: https://t.co/l9XKIUMihr Intended for HCPs only.
0
6
13
Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. @JCO_ASCO
ascopubs.org
We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line primary refractory/early relapsed (≤12 months) large...
0
7
35
Results of a pilot study led by investigators at @MSKCancerCenter showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @BloodPortfolio @DaniyanMd @AbdelWahablab Learn more:
0
15
52
🚨 Excited to share our new paper in Blood Cancer Journal! Optimization and validation of the International Metabolic Prognostic Index (IMPI) for CD19 CAR-T in LBCL 👉 https://t.co/cgrVsJeyM8 🧵 Key highlights below ⬇️
nature.com
Blood Cancer Journal - Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma
2
9
30
Perspective by J. Weberpals et al.: Opportunities for Causal Machine Learning in Precision Oncology https://t.co/YiQS2M6aEB
#AIinMedicine
2
13
32
Our manuscript using single cell RNA sequencing to compare two CD19 CAR T cell products, axi-cel and tisa-cel is online at JITC! @DrFredLocke @MoffittNews
https://t.co/cENQ8xCaDd . Our findings (thread):
jitc.bmj.com
Background Autologous CD19 chimeric antigen receptor (CAR) T-cell therapy leads to durable responses and improved survival in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL)....
4
21
73
How do gut and oral microbiota shape allogeneic BMT outcomes? In @GenomeMedicine, we introduce RATIO: a novel microbiome-informed machine learning model that predicts post-HCT outcome With @KorenLab, @nagler_EBMT & Oshrit Shtossel. 🔗 https://t.co/HmL1W7c3Ol
#HCT #machinelearning
genomemedicine.biomedcentral.com
Background Allogeneic hematopoietic stem cell transplantation (HSCT) is potentially curative for hematologic malignancies but is frequently complicated by relapse and immune-mediated complications,...
0
2
13
🚨 New in Nature Medicine: “Noncanonical and mortality-defining toxicities of CAR T cell therapy” As CAR-T moves beyond heme malignancies, we need a deeper understanding of rare & long-term toxicities. 🔗 https://t.co/uNcE2mBNUi PDF:
nature.com
Nature Medicine - This Review summarizes the current knowledge on mortality-defining toxicities of chimeric antigen receptor T cell therapies beyond cytokine-release syndrome and immune effector...
3
46
103
What is the exact impact of bridging radiation ☢️ (BRT) on CAR T efficacy/safety profile in NHL? BRT is wildly integrated in the bridging regimens but data are limited. Our meta-analysis (>500 pts) addresses this question and now out in @Haematologica
https://t.co/AoxOkRaGXU
1
7
23
Frail is not fail: Limited impact of comorbidities on non-relapse mortality and safety in patients with LBCL treated with CAR-T https://t.co/43kYYCnngV
0
13
32
Share your latest breakthroughs at the @COSTEMCongress - the premier meeting for cutting-edge debates in hematopoietic stem cell transplantation and cellular therapies. Abstract submission deadline: 15 July! Submit your work👇 https://t.co/vuXGdozHEc
0
5
19
Updated allogeneic stem cell donor guidelines from the CIBMTR/NMDP. A collaborative effort with many wonderful colleagues. Guidelines are adapted for donor selection when using PTCY. https://t.co/UqXxine4Sl
3
4
16
JCI - Clinical, tumor and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
1
5
10
Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now available online in Cancer Cell. #lmsm @washumedicine @MDAndersonNews. https://t.co/bA2BuZfEFI
cell.com
Li et al. use single nucleus sequencing of 217 large B cell lymphomas to identify microenvironment archetype profiles (LymphoMAPs), discovering their divergent biology and association with clinical...
4
29
86
We previously showed that IFNg is required for CAR-T efficacy in solid tumors, but is it always good? Here, we show that IFNg limits CD28 CAR-T cells and that protection from this signal drives greater antitumor activity and durability. Enjoy! https://t.co/W7SY1akJ6X
science.org
IFN-γ–resistant CD28 CAR T cells exhibit potent antitumor activity because of reduced cell death, increased expansion, and long-term memory formation.
3
23
107
🎉Finally out🎉 Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma Now in @BloodPortfolio Timely for #EHA2025🥰 #mmsm
https://t.co/J9OR1EPCzu
5
30
117